Treatment of community-acquired pneumonia: A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin

Chest

Volumn 103, Issue 3, 1993, Pages 697-701

  Chien, S M ^a   Pichotta, P ^a   Siepman, N ^a   Chan, C K ^a   Alexander, M ^a   Colohan, D ^a   Deschenes, G ^a   Doell, D V ^a   St Pierre, C ^a   Elfassy, B ^a   Goyette, M ^a   Grossman, R ^a   Grunfeld, A ^a   Plante, F ^a   Alestig, K ^a   Eilard, T ^a   Kalin, M ^a   Sundelof, B ^a  

^a WELLESLEY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN STEARATE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIAE; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; SCHOOL CHILD; THORAX RADIOGRAPHY; VOMITING;

EID: 0027411702     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.103.3.697     Document Type: Article

References (15)

1. JE Washington WR Wilson Erythromycin: a microbiological and clinical perspective after 30 years of clinical use Mayo Clin Proc 60 1985 189 203
2. HC Neu The development of macrolides: erythromycin in perspective J Antimicrob Chemother 27S A 1991 1 9
3. NX Chin NM Neu P Labthavikul G Saha HC Neu Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria Antimicrob Agents Chemother 31 1987 463 466
4. HA Kirst GE Sides New directions for macrolide antibiotics: structural modifications and in vitro activity Antimicrob Agents Chemother 33 1989 1413 1418
5. DJ Hardy RN Swanson RA Rode K Marsh NL Shipkowitz JJ Clement Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-erythromycin, its major metabolite in humans Antimicrob Agents Chemother 34 1990 1407 1413
6. EJ Barron SM Finegold Diagnostic microbiology 8th ed. 1990 CV Mosby St. Louis 192
7. JT MacFarlane MJ Word RG Finch AD MaCrae Hospital study of adult community acquired pneumonia Lancet 2 1982 255 258
8. E Bertsson J Blomberg T Lagergard B Trollfors Etiology of community acquired pneumonia patients requiring hospitalization Eur J Clin Microbiol 4 1985 268 272
9. RA Garibaldi Epidemiology of community acquired respiratory tract infections in adults Am J Med 78S 1985 32 37
10. RG Finch Epidemiological features and chemotherapy of community acquired respiratory tract infections J Antimicrob Chemother 26S E 1990 53 61
11. MA Woodhead JT MacFarlane JS McCracken DH Rose RG Finch Prospective study of the etiology and outcome of pneumonia in the community Lancet 1 1987 671 674
12. DJ Hardy DM Hensey JM Beyer C Vojtko EJ McDonald PB Fernandes Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides Antimicrob Agents Chemother 32 1988 1710 1719
13. GH Cassell J Drnec KB Waites MS Pate LB Duffy HL Watson Efficacy of clarithromycin against Mycoplasma pneumoniae J Antimicrob Chemother 27S A 1991 47 59
14. G Anderson TS Esmonde S Coles J Macklin A Carnegie A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community acquired pneumonia J Antimicrob Chemother 27S A 1991 117 124
15. P Hamedani J Ali S Hafeez R Bachand G Dawood S Quereshi The safety and efficacy of clarithromycin in patients with Legionella pneumonia Chest 100 1991 1503 1506